Novartis Aktie

99,60 EUR -2,40 EUR -2,35 %

15:28:23

STU

108,99 USD -2,46 USD -2,21 %

17:10:06

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

KGV16,45Div. Rendite3,37%

WKN907122

ISINUS66987V1098

SymbolNVS

Novartis Aktien News

Sortieren:Datum Meistgelesen

11.05.23GlobeNewswireNovartis to feature new PNH and CML scientific data from broad hematology portfolio at European Hematology Association Annual Meeting

09.05.23GlobeNewswireSandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars

04.05.23GlobeNewswireSandoz to exclusively commercialize six products in the US, reinforcing global leadership position in off-patent medicines

26.04.23GlobeNewswireNovartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

26.04.23GlobeNewswireNovartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO

26.04.23GlobeNewswireNovartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients

25.04.23GlobeNewswireNovartis erzielt kräftige Umsatzsteigerungen, eine robuste Margenerhöhung und wichtige Innovationsmeilensteine. Erhöhung der Jahresprognose

25.04.23GlobeNewswireNovartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance

20.04.23GlobeNewswireNovartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis

03.04.23GlobeNewswireSandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation

31.03.23GlobeNewswireNovartis Entresto receives positive CHMP opinion for pediatric heart failure

27.03.23GlobeNewswireNovartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer

21.03.23GlobeNewswireSandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation

20.03.23GlobeNewswireNovartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset

16.03.23GlobeNewswireNovartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer

09.03.23GlobeNewswireSandoz signs Memorandum of Understanding to build new biologics production plant in Slovenia, to support increasing global demand for biosimilar medicines

07.03.23GlobeNewswireAktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut

07.03.23GlobeNewswireNovartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting

20.02.23GlobeNewswireNovartis announces the appointment of the Chairman-Designate of Sandoz Board of Directors

01.02.23MyDividendsNovartis erhöht die Dividende das 26. Jahr in Folge

22.11.22GlobeNewswireNovartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH

07.11.22GlobeNewswireNew long-term Leqvio® (inclisiran) data from Novartis show sustained efficacy and safety over four years

07.11.22GlobeNewswireSandoz announces further investment in key manufacturing facility in Austria, to support increased global demand for essential antibiotics

25.10.22GlobeNewswireNovartis setzt die Wachstumsdynamik fort und bestätigt die Konzernprognose für das Geschäftsjahr 2022

25.10.22GlobeNewswireNovartis maintains growth momentum and confirms FY’22 Group guidance

24.10.22GlobeNewswireNovartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Phase III APPLY-PNH study

14.10.22GlobeNewswireNovartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer

22.09.22GlobeNewswireNovartis unveils new focused strategy, underpinned by eight potential multi-billion dollar peak sales brands & deep pipeline, at Meet the Management event

21.09.22GlobeNewswireNovartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenya® (fingolimod) dosing regimen patent

19.09.22GlobeNewswireSandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial

15.09.22GlobeNewswireNovartis statement regarding competition authority investigation into assertion of a patent

10.09.22GlobeNewswireNovartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials

09.09.22GlobeNewswireNovartis Kisqali® adds one more year of survival benefit for broadest set of patients, including those with aggressive HR+/HER2- advanced breast cancer

02.09.22GlobeNewswireNovartis highlights depth of immunology pipeline with novel data at key upcoming international congresses

01.09.22GlobeNewswireNovartis appoints Fiona Marshall, Ph.D., President of the Novartis Institutes for BioMedical Research as Jay Bradner, M.D., steps down from the Executive Committee of Novartis

30.08.22GlobeNewswireNovartis presents new data in breast and prostate cancer at ESMO

25.08.22GlobeNewswireNovartis will das Sandoz Geschäft durch eine hundertprozentige Ausgliederung als eigenständiges Unternehmen abspalten

25.08.22GlobeNewswireNovartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off

15.08.22GlobeNewswireNovartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer

25.07.22GlobeNewswireApplications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA

Novartis News

Novartis News: auf dieser Seite finden Sie alle Novartis News und Nachrichten zur Novartis Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novartis News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novartis News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.